Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Germline BRCA1/2 Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07039552
What this trial is testing

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands

Who this might be right for
Hereditary Breast and Ovarian Cancer SyndromeBRCA Mutations
Peking University Third Hospital 10,000
Large-scale testing (Phase 3)Study completedNCT02000622
What this trial is testing

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
AstraZeneca 302
Large-scale testing (Phase 3)Looking for participantsNCT06533384
What this trial is testing

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Who this might be right for
Triple-negative Breast Cancer
Guangdong Provincial People's Hospital 310
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Early research (Phase 1)Ended earlyNCT02561832
What this trial is testing

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 15
Large-scale testing (Phase 3)Active Not RecruitingNCT02032823
What this trial is testing

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,837
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Testing effectiveness (Phase 2)WithdrawnNCT03933761
What this trial is testing

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Who this might be right for
Ovarian CancerCarcinosarcoma
Australia New Zealand Gynaecological Oncology Group
Not applicableStudy completedNCT04987931
What this trial is testing

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 84
Testing effectiveness (Phase 2)Ended earlyNCT02034916
What this trial is testing

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 84
Not applicableStudy completedNCT02963688
What this trial is testing

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

Who this might be right for
To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer
Samsung Medical Center 298
Early research (Phase 1)Study completedNCT04991480
What this trial is testing

ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced CancerMetastatic CancerBreast Cancer
Artios Pharma Ltd 93
Not applicableActive Not RecruitingNCT07821229
What this trial is testing

Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)BRCA 1 Gene MutationBRCA 2 Gene Mutation
N.N. Petrov National Medical Research Center of Oncology 30
Not applicableUnknownNCT05763472
What this trial is testing

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

Who this might be right for
BRCA-Associated Breast Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 10
Large-scale testing (Phase 3)Study completedNCT03286842
What this trial is testing

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Who this might be right for
HER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 Mutations
AstraZeneca 256
Large-scale testing (Phase 3)Study completedNCT02184195
What this trial is testing

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Who this might be right for
Germline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas
AstraZeneca 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT03344965
What this trial is testing

Olaparib In Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerInvasive Breast CancerSomatic Mutation Breast Cancer (BRCA1)+7 more
Beth Israel Deaconess Medical Center 114
Large-scale testing (Phase 3)Looking for participantsNCT02000089
What this trial is testing

The Cancer of the Pancreas Screening-5 CAPS5)Study

Who this might be right for
Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more
Johns Hopkins University 9,000
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Not applicableLooking for participantsNCT05769517
What this trial is testing

Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries

Who this might be right for
BRCA MutationOvarian CancerUltrasound Therapy; Complications
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 6,465
Next Page